Market Access Brazil: Unlocking Pharma Potential
With this year’s election of president Dilma Rousseff, Brazil has indicated a willingness to encourage long-term foreign investment in the pharmaceutical industry. Yet while Rousseff has set three critical path priorities to ensure investment flows into the country, there are serious concerns. Price setting, the ‘big stick’ of the compulsory licenses, burdensome tax laws, slow product approvals and linguistic barriers have all emerged as key issues. Complicating matters is competition from government-favoured generics and a high volume in illegally-traded drugs, which represent 25 percent of all pharmaceuticals sold.
Yet while those issues may seem insurmountable, gaining access to the fast-growing and potentially rich Brazilian market is not impossible—with the right information.
Report overview
Market Access Brazil: Unlocking Pharma Potential lays bare the otherwise complex operations of the Brazilian health industry. From an examination of health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual property, the report provides clear insight into an evolving landscape. Containing interviews with experts, financial comparatives and updates from multinationals in the region, the report offers a compelling overview of Brazil’s pharmaceutical industry.
Key features
Yet while those issues may seem insurmountable, gaining access to the fast-growing and potentially rich Brazilian market is not impossible—with the right information.
Report overview
Market Access Brazil: Unlocking Pharma Potential lays bare the otherwise complex operations of the Brazilian health industry. From an examination of health care responsibilities and the role of the National Health Surveillance Agency (ANVISA) to consumer trends, the latest patent protection issues, the role of generics and ongoing battle over intellectual property, the report provides clear insight into an evolving landscape. Containing interviews with experts, financial comparatives and updates from multinationals in the region, the report offers a compelling overview of Brazil’s pharmaceutical industry.
Key features
- Breakdown of market trends and where opportunities exist
- Examination of intellectual property and price controls and their impact on foreign pharmaceutical manufacturers
- Role of generics, their phenomenal success and its impact on market share for the top ten producers
- Explanation of licensing agreements, their loopholes and legislation to close them
- Outline of investing within a protectionist environment, with a look at agreements that impact the pharma industry
- Company updates on Pfizer, sanofi-aventis, Laboratorios Silanes de Mexico, Amgen, Hypermarcas de Brazil and GlaxoSmithKline amongst others
- Clear insight into the complex and evolving regulatory landscape in Brazil
- A roadmap to the barriers and potholes facing multinationals
- Expert analysis of key issues facing the industry
- How is the political situation in Brazil impacting overseas investment by pharma?
- What barriers exist to market access and how can they be overcome?
- What are the emerging trends in intellectual property, licensing agreements and patent protection?
- What response has been made to questions about price control?
- Marin Osorio, Senior Secretary, Brazilian Ministry of Health
- Odinir Finotti, President, Pro Genericos
- Patrice Grand, Latin American affairs, Bristol-Myers Squibb
- Ricardo Mendes da Silva, President, Ache Laboratorios Farmaceuticos
- Maximilian Gorissen, Compustream Consultoria Ltda
- Ricardo Ruiz, Adjunct Professor, Federal University of Minas Gerais
- Emilio Wien, Health Economist, Brazilian Ministry of Health
EXECUTIVE SUMMARY
INTRODUCTION
THE BRAZILIAN PHARMACEUTICAL MARKET
Healthcare provision
Health sector responsibilities
ANVISA
Principal pharmaceutical patent legislation
Patent protection
Pharmaceutical patent applications (Jan 2001-Jan 2011)
Accessing the Brazilian pharmaceutical market
TRENDS IN THE BRAZILIAN PHARMACEUTICAL MARKET
Prescription Data for Brazil, 2009/10
Pharmaceuticals in Brazil, User Profile
Pharmaceutical Production in Brazil by Type of Capital, 2010
Intellectual Property
Generics
Estimated Market Shares of the Top 10 Pharma Companies in Brazil, June 2011
Licensing agreements
Measures to ensure the legality of medicines in Brazil
Interview with Marin Osorio, Senior Secretary, Ministry of Health
Price control
New reimbursement legislation
Multiple trade marks
The 'Pipeline Mechanism'
Investing within a protectionist environment
Establishing a presence in Brazil
The Brazilian market in comparative perspective
Pharma sector competitive infrastructure index in Latin American markets (June 2010)
Latin American pharmaceutical market sizes: Estimates and forecasts, 2009-14
Latin American agreements influencing Brazil's pharma industry
COMPANY UPDATES
The Brazilian pharmaceutical market: Some recent deals
Ache
Amgen
Bristol-Myers Squibb
Eurofarma
Novartis
Roche
INTRODUCTION
THE BRAZILIAN PHARMACEUTICAL MARKET
Healthcare provision
Health sector responsibilities
ANVISA
Principal pharmaceutical patent legislation
Patent protection
Pharmaceutical patent applications (Jan 2001-Jan 2011)
Accessing the Brazilian pharmaceutical market
TRENDS IN THE BRAZILIAN PHARMACEUTICAL MARKET
Prescription Data for Brazil, 2009/10
Pharmaceuticals in Brazil, User Profile
Pharmaceutical Production in Brazil by Type of Capital, 2010
Intellectual Property
Generics
Estimated Market Shares of the Top 10 Pharma Companies in Brazil, June 2011
Licensing agreements
Measures to ensure the legality of medicines in Brazil
Interview with Marin Osorio, Senior Secretary, Ministry of Health
Price control
New reimbursement legislation
Multiple trade marks
The 'Pipeline Mechanism'
Investing within a protectionist environment
Establishing a presence in Brazil
The Brazilian market in comparative perspective
Pharma sector competitive infrastructure index in Latin American markets (June 2010)
Latin American pharmaceutical market sizes: Estimates and forecasts, 2009-14
Latin American agreements influencing Brazil's pharma industry
COMPANY UPDATES
The Brazilian pharmaceutical market: Some recent deals
Ache
Amgen
Bristol-Myers Squibb
Eurofarma
Novartis
Roche
